Combination and Novel Pharmacologic Agents for OAB.
Whitney ClearwaterFarzaan KassamArshia Aalami HarandiChristopher F TenggardjajaNitya E AbrahamPublished in: Current urology reports (2022)
Combination therapies demonstrating greater efficacy than monotherapy include combination anticholinergics, anticholinergic plus β-3 agonist, and anticholinergic with behavioral modification, percutaneous tibial nerve stimulation, or sacral neuromodulation. Promising novel therapies include new bladder selective anticholinergics, new β-3 agonists, and gabapentin. OAB is a symptom complex caused by dysfunction in the interconnected neural, muscular, and urothelial systems that control micturition. Although several therapeutic targets and treatment options exist, complete resolution is not always achieved, discontinuation rate for medical therapy is high, and few patients subsequently progress to third-line treatment options. Recent literature suggests combination therapy diversifying therapeutic targets is more effective than targeting a single pathway and novel treatments targeting additional pathways have promising results.
Keyphrases
- combination therapy
- end stage renal disease
- ejection fraction
- urinary tract
- chronic kidney disease
- newly diagnosed
- cancer therapy
- systematic review
- healthcare
- spinal cord injury
- oxidative stress
- total knee arthroplasty
- peritoneal dialysis
- minimally invasive
- clinical trial
- single molecule
- mesenchymal stem cells
- patient reported outcomes
- resistance training
- cell therapy
- body composition